Screener
BridgeBio Pharma BBIO Interest Income
Interest Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Total operating costs and expenses | 300,471 | 221,005 |
| Loss from operations | (105,956) | (104,372) |
| Other income (expense), net: | ||
| Interest income | 6,246 | 5,385 |
| Interest expense | (12,942) | (18,121) |
| Noncash interest expense on deferred royalty obligations (1) | (39,873) | (24,020) |
| Loss on extinguishment of debt | — | (21,155) |
| Net loss from equity method investments | (18,283) | (15,556) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's interest income?
- BridgeBio Pharma (BBIO) reported interest income of $6.25M in Q1 2026.
- How has BridgeBio Pharma's interest income changed year-over-year?
- BridgeBio Pharma's interest income increased by 16.0% year-over-year, from $5.39M to $6.25M.
- What is the long-term trend for BridgeBio Pharma's interest income?
- Over 4 years (2021 to 2025), BridgeBio Pharma's interest income has grown at a 104.6% compound annual growth rate (CAGR), from $1.13M to $19.85M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about BridgeBio Pharma's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude